MentionFox
Home › Executive changes › Cue Biopharma, Inc.
Leadership changes · SEC Form 8-K, Item 5.02

Cue Biopharma, Inc. executive changes

Every leadership change Cue Biopharma, Inc. reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings2
Appointments named3
Latest filing2026-06-02

Cue Biopharma, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-06-02. Between them they name 3 people. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-06-02 · 8-K

Appointed: Sumita Ray, Corporate Secretary, effective 2026-06-01

(b) On June 1, 2026, the Board appointed Sumita Ray, JD, as the Company's Chief Legal & Compliance Officer and Corporate Secretary, effective June 1, 2026.

Appointed: Michael Meluzio, Vice President, Principal Accounting Officer, effective 2026-06-01

(c) On June 1, 2026, the Board appointed Michael Meluzio as the Company's Vice President, Principal Accounting Officer, to serve as the Company's principal accounting officer, effective June 1, 2026.
Filed 2026-05-01 · 8-K

Appointed: Lee Lin, President and Chief Executive Officer

In connection with her appointment as President and Chief Executive Officer, Dr. Lin will serve as the Company's principal executive, accounting and financial officer.
Hiring for a seat like this?

Find people with the same kind of experience as the Corporate Secretary at Cue Biopharma, Inc., with the record behind each one.

Find candidates like Corporate Secretary at Cue Biopharma, Inc.
Selling to Cue Biopharma, Inc.?

New leaders review vendors and budgets in their first months. Get an alert the next time Cue Biopharma, Inc. is in the news or changes leadership.

Get an alert when Cue Biopharma, Inc. changes leadership

Tools for this story

Each opens in a new tab, filled in for Cue Biopharma, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/cue-biopharma
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
Cue Biopharma, Inc. (CUE) executive changes: Sumita Ray appointed, Corporate Secretary. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/cue-biopharma